Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Shire Exits Biosimilars, Streamlines Oncology Business

Executive Summary

Terminating a pair of biosimilar partnerships inherited from Baxalta will better enable Shire to focus on core strengths, CEO Ornskov says. The firm will use Baxalta assets to gradually develop a cancer franchise.


Related Content

Shire's Ornskov On Goals And Accomplishments One Year After Baxalta Merger
Shire’s Sales, R&D Heads Shed Light On The Post-Baxalta Road Ahead
Biosimilar Dealmaking Moves The Needle Forward
Shire Builds Confidence In $20bn Revenue Target
Shire Plays Up Xiidra Launch, Downplays Missed Sales Expectations
Merck KGaA To Exit Biosimilars? That Would Be No Surprise To Analysts
Despite Pricing Pressure, Humira Performing Strongly Across Most Metrics, Abbvie Says
Merrimack's Slow Ramp-up For Onivyde Prompts Cutbacks
CTI BioPharma’s Pacritinib Meets One Co-Primary Endpoint, Just Misses Another, In PERSIST-2
Shire Is Agnostic On Baxalta's Biosimilars Pipeline As Integration Begins


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts